KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Recursion Pharmaceuticals (RXRX) Long-Term Debt Repayments: 2020-2025

Historic Long-Term Debt Repayments for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $2.1 million.

  • Recursion Pharmaceuticals' Long-Term Debt Repayments fell 7.00% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year increase of 175.60%. This contributed to the annual value of $4.4 million for FY2024, which is 479.63% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Long-Term Debt Repayments stood at $2.1 million, which was up 2.06% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Long-Term Debt Repayments ranged from a high of $12.7 million in Q3 2021 and a low of $20,000 during Q1 2021.
  • For the 3-year period, Recursion Pharmaceuticals' Long-Term Debt Repayments averaged around $1.0 million, with its median value being $694,000 (2023).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Long-Term Debt Repayments skyrocketed by 63,585.00% in 2021 and then plummeted by 99.82% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Long-Term Debt Repayments (Quarterly) stood at $21,000 in 2021, then increased by 9.52% to $23,000 in 2022, then skyrocketed by 2,917.39% to $694,000 in 2023, then skyrocketed by 202.74% to $2.1 million in 2024, then dropped by 7.00% to $2.1 million in 2025.
  • Its Long-Term Debt Repayments stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.0 million for Q1 2025.